{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:54:38Z","timestamp":1782222878548,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00059-021-05024-3","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T05:29:23Z","timestamp":1612934963000},"page":"217-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Heart failure in advanced chronic kidney disease: treatment rationale","Herzinsuffizienz bei fortgeschrittener Niereninsuffizienz: Grundprinzip der Behandlung"],"prefix":"10.1007","volume":"46","author":[{"given":"N.","family":"Marx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"5024_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"Anonymous","year":"1999","unstructured":"Anonymous (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a\u00a0randomised trial. Lancet 353:9\u201313","journal-title":"Lancet"},{"key":"5024_CR2","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Anonymous","year":"1999","unstructured":"Anonymous (1999) Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001\u20132007","journal-title":"Lancet"},{"key":"5024_CR3","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","volume":"58","author":"SV Badve","year":"2011","unstructured":"Badve\u00a0SV, Roberts\u00a0MA, Hawley\u00a0CM et al (2011) Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a\u00a0systematic review and meta-analysis. J\u00a0Am Coll Cardiol 58:1152\u20131161","journal-title":"J Am Coll Cardiol"},{"key":"5024_CR4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"5024_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/j.ajkd.2017.12.006","volume":"72","author":"AA House","year":"2018","unstructured":"House\u00a0AA (2018) Management of heart failure in advancing CKD: core curriculum 2018. Am J Kidney Dis 72:284\u2013295","journal-title":"Am J Kidney Dis"},{"key":"5024_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ Mcmurray","year":"2014","unstructured":"Mcmurray\u00a0JJ, Packer\u00a0M, Desai\u00a0AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"5024_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV Mcmurray","year":"2019","unstructured":"Mcmurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"issue":"15","key":"5024_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N\u00a0Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"5024_CR9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer\u00a0M, Bristow\u00a0MR, Cohn\u00a0JN et\u00a0al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N\u00a0Engl J Med 334:1349\u20131355","journal-title":"N Engl J Med"},{"key":"5024_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD et\u00a0al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 18:891\u2013975","journal-title":"Eur J Heart Fail"},{"key":"5024_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad\u00a0F, Mcmurray\u00a0JJ, Krum\u00a0H et\u00a0al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 364:11\u201321","journal-title":"N Engl J Med"},{"issue":"5","key":"5024_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11897-018-0406-8","volume":"15","author":"M Arrigo","year":"2018","unstructured":"Arrigo\u00a0M, Cipp\u00e0\u00a0PE, Mebazaa\u00a0A (2018) Cardiorenal interactions revisited: how to improve heart failure outcomes in patients with chronic kidney disease. Curr Heart Fail Rep 15(5):307\u2013314","journal-title":"Curr Heart Fail Rep"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05024-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-021-05024-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05024-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T07:08:56Z","timestamp":1623308936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-021-05024-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5024"],"URL":"https:\/\/doi.org\/10.1007\/s00059-021-05024-3","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"13 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"N.\u00a0Marx has received support for clinical trial leadership from Boehringer Ingelheim, Novo Nordisk, served as a\u00a0consultant to Boehringer Ingelheim, Merck, Novo Nordisk, AstraZeneca, BMS, received grant support from Boehringer Ingelheim, Merck, Novo Nordisk, and served as a\u00a0speaker for Boehringer Ingelheim, Merck, Novo Nordisk, Lilly, BMS, and Astra Zeneca. N.\u00a0Marx declines all personal compensation from pharma or device companies. J.\u00a0Floege served as a\u00a0consultant to Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}